IMC-002

· ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for IMC-002, covering 2024-08-02 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy [Phase 1]